Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2009

View Archived Issues

Reduced fractures with denosumab in postmenopausal women and men with prostate cancer

Studies with HC-056456 reveal CatSper channels as a target for blocking fertility

rAAV1-AAT gene therapy shows promise for future development in phase I trial

Doxorubicin derivative INNO-206 more potent than free doxorubicin in vivo

Merck & Co. to assess safety/efficacy of MK-2578 in kidney disease patients in phase II trial

Safety and efficacy of JTT-130 to be evaluated in obese type 2 diabetic patients

Bayer relegates clinical trials for alemtuzumab to Genzyme Japan

Bevacizumab plus erlotinib therapy shows activity in phase II clinical trial in HCC

Can-Fite BioPharma reports results from its phase II CF-101 trial in psoriasis

Opexa Therapeutics reports additional data with Tovaxin for multiple sclerosis

Novel PARP inhibitors presented by AstraZeneca for cancer therapy

R-Tech Ueno presents VAP-1 inhibitors for macular edema and other eye conditions

Akela undergoes corporate restructuring

PPARgamma agonists for the treatment of AD described by GlaxoSmithKline

Panacea Biotec discloses DPP-IV inhibitors for the treatment of type 2 diabetes

NeuroSearch patents novel dopamine and serotonin receptor ligands as antipsychotics

Luminex receives 510(k) clearance for new cystic fibrosis test

XenoPort reports results from a safety and tolerability trial of arbaclofen

LigoCyte initiates phase I/II study of nasally delivered dry powder norovirus vaccine

Shire provides update on velaglucerase alfa for Gaucher's disease

GlycoMimetics begins pilot study of GMI-1070 in sickle cell patients

Dor BioPharma receives NIH grant to support phase I/II DOR-201 trial in radiation enteritis

Evotec commences phase I trial of EVT-103

Ark Therapeutics receives feedback from MHRA on EG-013

Bayer Schering submits IND for phase I MN-IC trial, triggering milestone payments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...